2024 Volume 50 - Canada Communicable Disease Report (CCDR)

ISSN: 1481-8531

2024 Volume 50

CCDR Volume 50-12, December 2024: Tuberculosis

• Summary of the National Advisory Committee on Immunization (NACI) Statement: Updated guidance on human papillomavirus (HPV) vaccines
• Popularity of HIV self-tests may say more about the state of our primary care system than about the device itself
• Mycobacterium tuberculosis pseudo-outbreak due to laboratory cross-contamination: A molecular epidemiology outbreak investigation
• Epidemiological analysis of paediatric tuberculosis infection in northern Saskatchewan First Nations communities, 2018–2022
• Bats and Rabies in Canada
• Thank you to the CCDR peer reviewers 2024

CCDR Volume 50-11, November 2024: Influenza Vaccination

• Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2024–2025
• Summary of the National Advisory Committee on Immunization (NACI) Supplemental Guidance on Influenza Vaccination in Adults 65 Years of Age and Older
• National Influenza Annual Report 2023–2024: A focus on influenza B and public health implications
• Perspectives on blastomycosis in Canada in the face of climate change
• Locally acquired typhoid fever outbreak linked to chronic carriage in Ottawa, Canada, 2018–2022

CCDR Volume 50-10, October 2024: COVID-19 after the pandemic

• Lessons learned from COVID-19: Harnessing community insights for better vaccination outcomes
• Evidence brief on facilitators, barriers and hesitancy of COVID-19 booster doses in Canada
• Mathematical modelling for pandemic preparedness in Canada: Learning from COVID-19
• An innovative tool to prioritize the assessment of investigational COVID-19 therapeutics: A pilot project
• Large scale analysis of the SARS-CoV-2 main protease reveals marginal presence of nirmatrelvir-resistant SARS-CoV-2 Omicron mutants in Ontario, Canada, December 2021–September 2023
• Opportunities and lessons learned from a retrospective analysis of administrative billing data to understand the language profile of high-risk close contacts of COVID-19 cases in Ontario

CCDR Volume 50-9, September 2024: Health Risk Assessment

• Estimating public health risks of infectious disease events: A Canadian approach to rapid risk assessment
• Public health contributions of entomological surveillance of West Nile virus (WNV) and other mosquito-borne arboviruses in a context of climate change
• Human echinococcosis incidence in Canada: A retrospective descriptive study using administrative hospital and ambulatory visit data, 2000–2020
• Prevalence and correlates of oral antibiotic use in Canada
• Epidemiology of sporadic and outbreak-associated hepatitis A infections in Ontario, Canada: A descriptive summary, 2015–2022

CCDR Volume 50-7/8, July/August 2024: Sexual Health

• Summary of the National Advisory Committee on Sexually Transmitted and Blood-Borne Infections (NAC-STBBI) Statement: Recommendations on Screening for Syphilis in Non-Pregnant Adults and Adolescents
• Exploring the need for sexually transmitted infection education among university student athletes in Saskatchewan
• Acceptability, feasibility, equity and resource use for prenatal screening for chlamydia and gonorrhea: A systematic review
• HIV among African, Caribbean and Black people in Ontario
• Social capital interventions for human papillomavirus (HPV) immunization and cervical cancer screening: A rapid review
• Congenital rubella syndrome, a case series

CCDR Volume 50-6, June 2024: Cancer Vaccines

• Efficacy, effectiveness and immunogenicity of reduced HPV vaccination schedules: A review of available evidence
• Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2018–2022
• Device and surgical procedure-related infections in Canadian acute care hospitals, 2018−2022
• Thematic description of factors linked with extended-spectrum beta-lactamase-producing Enterobacteriaceae in humans
• Characteristics associated with SARS-CoV-2 testing, infection and vaccine uptake among essential non-healthcare workers in Montréal, 2021

CCDR Volume 50-5, May 2024: CCDR 50th Anniversary

• Canada Communicable Disease Report—50 years later
• Invasive pneumococcal disease surveillance in Canada, 2021–2022
• Invasive group A streptococcal disease surveillance in Canada, 2021–2022
• Canadian laboratory incidents with human pathogens and toxins: An overview of reports, 2016–2022
• Outbreak of Human Trichinellosis — Arizona, Minnesota, and South Dakota, 2022
• An outbreak of Salmonella Infantis linked to shredded pork products from an unlicensed source in multiple health districts, Ontario, Canada, 2021

CCDR Volume 50-3/4, March/April 2024: Innovations in Public Health Surveillance

• Summary of the National Advisory Committee on Immunization (NACI) Updated Guidance on Influenza Vaccination During Pregnancy
• Innovations in public health surveillance: An overview of novel use of data and analytic methods
• Commentary on the adoption of a test-based versus syndromic-based approach to outbreak declaration and management in hospital and institutional settings
• Impact of the COVID-19 pandemic on inbound air travel to Canada
• Microbiology of bloodstream infections in Ontario, Canada during COVID-19 pandemic

CCDR Volume 50-1/2, January/February 2024: Respiratory Syncytial Virus (RSV)

• Burden of disease of respiratory syncytial virus in infants, young children and pregnant women and people
• Canadian vaccine safety surveillance reports following immunization with seasonal influenza vaccines, 2021–2022
• Disease burden attributable to respiratory syncytial virus outbreaks in long-term care
• PCV13, PCV15 or PCV20: Which vaccine is best for children in terms of immunogenicity?
• COVID-19 outcome trends by vaccination status in Canada, December 2020–January 2022
• National safety monitoring of vaccines from the Canadian Adverse Events Following Immunization Surveillance System (CAEFISS), 2018–2019
• Wastewater surveillance for COVID-19 in shelters: A creative strategy for a complex setting
• Evolution of illness severity in hospital admissions due to COVID-19, Québec, Canada, January to April 2022
• Epidemiological characteristics of human infections with avian influenza A(H5N6) virus, China and Laos: A multiple case descriptive analysis, February 2014–June 2023